Sentences with phrase «disease therapeutic development»

Not exact matches

Mannkind, which focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, entered a shallow but persistent downtrend in 2004, posting a series of lower highs into 2015.

These plaques are associated with development of Alzheimer's disease and several therapeutic strategies are aimed at reducing their formation and eliminating them.

The next objective of the researchers is to decode the action mechanism of TREX2 in the development and maintenance of psoriasis, so as to design new therapeutic strategies for the treatment of this disease.

The research, led by researchers from the Department of Pathology and Experimental Therapeutics of the Faculty of Medicine and Health Sciences of the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL), contributes to increase the knowledge about this complex and multi-factor inflammatory disease and opens doors to the development of new therapeutic strategies.

As a result, the emphasis in early development is on understanding the molecular underpinnings of disease and developing markers for therapeutic effects.

To strengthen its clinical research profile, Dresden has created a strategic plan, to be funded by the German Research Ministry (BMBF), that focuses on three aspects of clinical research: tissue engineering and development of physical and molecular medical technologies for clinical application; therapeutic strategies after cell and tissue damage; and diagnosis and therapy of malignant diseases.

Co-lead author, Doctor Mohammed Eslam, said this discovery holds great promise for the development of effective therapeutic treatments for liver disease.

Professor Fallon said: «This identification of an early stage cellular checkpoint that can act as a break on allergic responses has important implications for the development of new therapeutic approaches for asthma and other allergic diseases.»

The findings provide insight into the biological pathways that may predispose an individual to disease and could ultimately lead to the development of new therapeutic avenues to treat the five major psychiatric illnesses.

The role of Apelin and Elabela in establishing the circulatory system makes them potential targets in future development of therapeutic applications for illnesses ranging from the various cancers, and cardiovascular diseases, to even metabolic diseases such as diabetes.

Now, researchers may finally understand an important mechanism that keeps this friendly truce intact — a finding that may lead to the development of new therapeutic strategies for such chronic diseases.

While still early in development, stem and therapeutic cells may one day offer effective treatments against diseases, particularly cancer.

To date, there are no cures available for PH. Little is known about the mechanisms underlying these diseases, an understanding essential to development of therapeutic strategies.

The study of these new mouse models means an advance in the knowledge of disease's development mechanisms and an opportunity to implement new therapeutic strategies for patients.

«The dBET1 and the dFKBP12 compounds are presently in a late stage of lead optimization for therapeutic development in both cancer and non-malignant diseases,» says Prem Das, PhD, chief research business development officer at Dana - Farber.

Calling their compound a new therapeutic candidate for people with severe asthma and other chronic airway diseases, researchers say with additional research and development their discovery could lead to future clinical trials for asthma, Cystic Fibrosis and Chronic Obstructive Pulmonary Disease (COPD).

Targeted gene therapies, however, had to wait for (1) the identification of the genes to target, (2) the cloning and / or sequencing of the relevant genes and in some cases, the specific disease - causing variant, (3) a full understanding of the normal gene function and regulation, and (4) the development of efficient ways to deliver genes to the relevant tissues at therapeutic levels.

ISIS PHARMACEUTICALS» FORWARD - LOOKING STATEMENT This press release includes forward - looking statements regarding the discovery, development and potential of drugs for severe and rare diseases, and the development, activity, therapeutic potential and safety of ISIS - SMNRx.

Supports work that can accelerate neurotrophic factor therapeutic development for Parkinson's disease (PD).

The Ospedale San Raffaele Mouse Clinic (OMC) is the follow - up and consolidation of a Regione Lombardia - funded project (EMDM), which aimed at the establishment and implementation of a large, dedicated facility (the European Mouse Disease Models Center) whose goal is the development and functional assessment of mouse disease models, both for the dissection of the underlying pathogenic mechanisms and for the screening and validation of innovative diagnostic and therapeutic procDisease Models Center) whose goal is the development and functional assessment of mouse disease models, both for the dissection of the underlying pathogenic mechanisms and for the screening and validation of innovative diagnostic and therapeutic procdisease models, both for the dissection of the underlying pathogenic mechanisms and for the screening and validation of innovative diagnostic and therapeutic procedures.

This call for projects «Mouse models and rare diseases» aims to give a significant boost to the development of mouse models, in order to: ◊ gain a better understanding of the pathophysiological mechanisms involved in rare diseases whose defective genes have been identified ◊ test and validate therapeutic proofs of concept, at the pre-clinical in vivo level Indeed, producing these models meets a key objective in the development of a therapeutic strategy.

Supports work that can accelerate neurotrophic factor therapeutic development for Parkinson's Disease.

Considering the vast population of patients with these diseases, the development of CXCR4 antagonists is of therapeutic as well as economic importance.

The condition is more common than muscular dystrophy and cystic fibrosis, but the development of new therapeutic concepts is hindered by the fact that unlike muscular dystrophy and cystic fibrosis, where a single mutated gene causing the disease is known, the entire human chromosome 21 (containing around 300 genes) still has to be dissected into individual gene - dose contributions to the DS symptoms.

The use of NHP in biomedical research is justified in the studies of human diseases, to learn more about their causal pathways, their development, their infectiveness and to develop therapeutic and preventive strategies.

«This collaboration has already resulted in exciting new capabilities and insights for R&D for small airway diseases, and we look forward to further advancing the application of the Organ - Chips to improve therapeutic development».

With the reference cell census data in hand, the research team is excited to conduct additional studies, including ones involving models or human patients with gastrointestinal conditions — Crohn's disease, ulcerative colitis, gastrointestinal cancers, forms of food allergy, etc. — aimed at identifying changes in gene expression and epithelial structure and function that could reveal new insights and opportunities for therapeutic development.

Our first liver therapeutic development program is for methylmalonic acidemia (MMA), a serious and often life - threatening rare liver disease; it is primarily a pediatric disease with onset in early infancy.

Objective: To provide data - driven and computational infrastructures and data - sharing platforms to support large - scale, system - level data integration and modeling, and enable predictive biology for pathogens and host - pathogen interactions for discovery research, clinical investigation, and therapeutic development for infectious diseases.

PHENOMIN - ICS offers to generate genetically modified mouse models on a high - throughput and large scale basis, and then to provide a first phenotyping characterisation, either standardised or more specific, for a better understanding of disease mechanisms and for the development of new therapeutic treatments.

Importantly, newly identified proteins will serve as disease biomarkers and will contribute to the development of novel therapeutic strategies.

Data from a new study on how antibodies are developed in humans can be utilized to improve the development of therapeutic antibodies for treating human diseases.

Because of the laboratory's success in its study of immune response, Sette and his team believe their research will lead to development of new therapeutic and prophylactic approaches to fighting infectious diseases.

Wayne C. Drevets, M.D. is the Scientific Vice President and Disease Area Leader in Mood Disorders in the Neuroscience Therapeutic Area at Janssen Research & Development, of Johnson & Johnson, Inc..

In this protein, the binding domain of botulinum toxin is replaced to broaden the toxin's therapeutic potential and allow drug development to be targeted towards a specific disease.

«We think this development will help other scientists better utilize open data, hopefully leading to the discovery of new therapeutic targets for disease,» says first author Andra Waagmeester, PhD, formerly a researcher at Maastricht University and now CEO of the start - up company Micelio.

«This development allows us to study genetic diseases more easily and potentially identify new therapeutic targets.»

The ambition of I - Stem is to develop a research technology capable of covering all aspects of discovery and development of therapeutic molecules for pre-clinical trials as defined by clinical and epidemiological studies of monogenic diseases, until a candidate molecule is identified for clinical trials.

The autoimmune therapeutic area represents a broad category of human disease presentations that involve a variety of organ targets and thus presents a significant challenge with respect to the development of therapies designed to re-establish self - tolerance.

Thus, all research on lines of human embryonic stem cells as the cells of various phenotypes derived from these lines should aim to lexploration mechanisms or the development and validation of therapeutic applicable to serious diseases.

«Biomarkers are critical to accelerating therapeutic development for any disease.

One outcome of such studies might be the development of novel biomarkers of disease states, adverse responses, beneficial responses, exposures, or therapeutic responses.

We have also set out to exploit the specificity of carbohydrate recognition and the ensuing membrane mechanical potential resulting from clustering of glycosphingolipids for the development of innovative therapeutic delivery strategies for the treatment of cancer and infectious disease.

The results are «important both for mechanistic study and also for potentially therapeutic developments,» said Yadong Huang of the University of California, San Francisco, and the Gladstone Institute of Neurological Disease, who also was not involved in the work.

These results not only change our fundamental understanding of what exactly goes wrong in the muscles of Duchenne muscular dystrophy patients, but they argue for a very different approach to therapeutic development for this devastating disease.»

In the U.S., orphan drug designation is granted by the FDA's Office of Orphan Products Development to promote the development of products that may offer therapeutic benefits for diseases with a prevalence of fewer than 200,000 individualDevelopment to promote the development of products that may offer therapeutic benefits for diseases with a prevalence of fewer than 200,000 individualdevelopment of products that may offer therapeutic benefits for diseases with a prevalence of fewer than 200,000 individuals per year.

Translational medicine is the integrated application of innovative pharmacology tools, biomarkers, clinical methods, clinical technologies and study designs to improve disease understanding, confidence in human drug targets and increase confidence in drug candidates, understand the therapeutic index in humans, enhance cost - effective decision making in exploratory development and increase phase II success.

The HapMap will allow the discovery of sequence variants that affect common disease, will facilitate development of diagnostic tools, and will enhance our ability to choose targets for therapeutic intervention.

Our aim is the development of novel, disease - modifying therapeutic approaches for protein misfolding neurodegenerative diseases.

This study leads to a better understanding of macrophage responses to infection, provides insight into disease development, and suggests targets for therapeutic intervention.